Pyelonephritis Diagnosis and Treatment

Clinical Presentation

The American College of Physicians recommends that pyelonephritis typically presents with fever (>38°C), flank pain or costovertebral angle tenderness, and systemic symptoms including chills, nausea, vomiting, malaise, and fatigue 1, 2
Fever is present in most cases, though it may be absent early in illness or in elderly, diabetic, or immunocompromised patients 1, 2
Flank pain or costovertebral angle tenderness is nearly universal and its absence should raise suspicion of alternative diagnoses 2
Lower urinary tract symptoms (urgency, dysuria, frequency) may accompany upper tract symptoms but are absent in up to 20% of patients 2
Up to 50% of diabetic patients lack typical flank tenderness, making clinical diagnosis more challenging and requiring higher suspicion for complications 1, 2
Elderly and immunocompromised patients may present atypically without fever or classic symptoms 2

Urinalysis showing pyuria and/or bacteriuria is the key diagnostic test, with the combination of leukocyte esterase and nitrite tests having 75-84% sensitivity and 82-98% specificity 2
Urine culture with antimicrobial susceptibility testing must be obtained in all cases before initiating antibiotics 3, 1
Urine culture yielding >10,000 CFU/mL of a uropathogen confirms the diagnosis 2
Blood cultures should be reserved for patients who appear systemically ill, have high fever, are immunocompromised, or have uncertain diagnosis 1
Initial imaging is NOT indicated for uncomplicated pyelonephritis 1, 2
Imaging should be performed only if the patient remains febrile after 72 hours of appropriate antibiotic therapy or experiences clinical deterioration 1, 2
Early imaging is warranted in high-risk populations: diabetic patients, immunocompromised patients, those with history of urolithiasis, anatomic abnormalities, or suspected obstruction 1, 2
Ultrasound is the preferred initial imaging modality to evaluate for obstruction, abscess, or stones; contrast-enhanced CT if ultrasound is inconclusive 1, 2

For outpatient treatment, fluoroquinolones are the preferred first-line agents when local resistance rates are ≤10% 3, 4
Ciprofloxacin 500-750 mg twice daily for 5-7 days is a recommended oral regimen 3, 4, 1
Levofloxacin 750 mg once daily for 5 days is a recommended oral regimen 3, 4, 1
Trimethoprim-sulfamethoxazole 160/800 mg twice daily for 14 days is a recommended oral regimen (only when susceptibility is confirmed) 3, 4
When local fluoroquinolone resistance exceeds 10%, give one initial dose of a long-acting parenteral antibiotic (ceftriaxone 1g IV or gentamicin 5-7 mg/kg IV) before starting oral fluoroquinolone 3, 4
Oral beta-lactams are generally inappropriate for empiric therapy due to high resistance rates 3
TMP-SMX should not be used empirically without culture and susceptibility data due to high resistance rates 3, 4
Patients requiring hospitalization should initially receive intravenous antimicrobial therapy 3, 1
Ciprofloxacin 400 mg IV twice daily is a recommended parenteral regimen 1
Levofloxacin 750 mg IV once daily is a recommended parenteral regimen 1
Ceftriaxone 1-2 g IV once daily is a recommended parenteral regimen 3, 1
Standard treatment duration is 7-14 days total 3, 1
Transition to oral therapy when patient is afebrile for 24-48 hours, based on culture sensitivities 1
95% of patients with uncomplicated pyelonephritis become afebrile within 48 hours, and nearly 100% within 72 hours of appropriate therapy 1, 2

Persistent fever after 72 hours of appropriate antibiotics warrants imaging to rule out complications (obstruction, abscess, stone disease) 1, 2
Common complications to consider include renal or perinephric abscess, urinary tract obstruction, and emphysematous pyelonephritis (especially in diabetic patients) 1, 2